GiurgescuCNowakALGillespieSNolanTSAndersonCMFordJLet al
After 48 weeks, or nearly a year, more than 97% of patients in both groups were free from relapses 97.2% of those who always received the subcutaneous formulation and 98.1% of patients who were initially treated with Ocrevus
Among patients with T2D, higher income was associated with lower discontinuation
This review summarizes completed and ongoing clinical trials of triple agonists, with a focus on retatrutidethe most advanced candidate to date
C57BL/6J wild-type (WT) mice were purchased from Jackson Laboratory (Bar Harbor, ME)
However, while specific populations (such as subjects with documented zinc deficiency or at risk of severe malnutrition) appear to greatly benefit from zinc supplementation in terms of thyroid function, the role of zinc supplementation in the general population as a protective factor for thyroid disorders is still not fully established [62]